These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 37155496

  • 1. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England.
    Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
    [Abstract] [Full Text] [Related]

  • 2. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study.
    Moretz C, Sharpsten L, Bengtson LG, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1721-1737. PubMed ID: 31534326
    [Abstract] [Full Text] [Related]

  • 3. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJF, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2039-2054. PubMed ID: 37731774
    [Abstract] [Full Text] [Related]

  • 4. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG.
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [Abstract] [Full Text] [Related]

  • 5. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
    Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.
    BMC Pulm Med; 2021 Jul 31; 21(1):253. PubMed ID: 34332555
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England.
    Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Jul 31; 18():1431-1444. PubMed ID: 37465818
    [Abstract] [Full Text] [Related]

  • 7. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study.
    Wang MT, Lai JH, Huang YL, Liou JT, Cheng SH, Lin CW, Pan HY, Hsu YJ, Tsai CL.
    Chest; 2021 Oct 31; 160(4):1255-1270. PubMed ID: 34023320
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
    Moretz C, Cole AL, Mu G, Wu B, Guisinger A, Liu Y, Hahn B, Baylis L.
    Int J Chron Obstruct Pulmon Dis; 2020 Oct 31; 15():2207-2215. PubMed ID: 32982213
    [Abstract] [Full Text] [Related]

  • 9. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Oct 31; 18():231-245. PubMed ID: 36908830
    [Abstract] [Full Text] [Related]

  • 10. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
    Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG.
    Adv Ther; 2022 Sep 31; 39(9):3957-3978. PubMed ID: 35849317
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
    McCormack M, Paczkowski R, Gronroos NN, Noorduyn SG, Lee L, Veeranki P, Johnson MG, Igboekwe E, Kahle-Wrobleski K, Panettieri R.
    Adv Ther; 2024 Mar 31; 41(3):1245-1261. PubMed ID: 38310193
    [Abstract] [Full Text] [Related]

  • 12. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
    Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022 Mar 31; 17():1455-1466. PubMed ID: 35769225
    [Abstract] [Full Text] [Related]

  • 13. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022 Mar 31; 17():1781-1795. PubMed ID: 35983168
    [Abstract] [Full Text] [Related]

  • 14. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
    Mannino D, Bogart M, Wu B, Germain G, Laliberté F, MacKnight SD, Jung Y, Stiegler M, Duh MS.
    Respir Med; 2022 Jun 31; 197():106807. PubMed ID: 35429764
    [Abstract] [Full Text] [Related]

  • 15. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
    Palli SR, Xie B, Chastek B, Elliott CA, Bengtson LGS.
    J Manag Care Spec Pharm; 2021 Jul 31; 27(7):810-824. PubMed ID: 33764161
    [Abstract] [Full Text] [Related]

  • 16. Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study.
    Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R, Compton C, Ismaila A.
    BMJ Open; 2024 Feb 07; 14(2):e072361. PubMed ID: 38326272
    [Abstract] [Full Text] [Related]

  • 17. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
    Sliwka A, Jankowski M, Gross-Sondej I, Storman M, Nowobilski R, Bala MM.
    Cochrane Database Syst Rev; 2018 Aug 24; 8(8):CD012355. PubMed ID: 30141826
    [Abstract] [Full Text] [Related]

  • 18. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
    Ismaila AS, Rothnie KJ, Wood RP, Banks VL, Camidge LJ, Czira A, Compton C, Sharma R, Millard SN, Massey O, Halpin DMG.
    Respir Res; 2023 Sep 25; 24(1):229. PubMed ID: 37749551
    [Abstract] [Full Text] [Related]

  • 19. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
    Moretz C, Hahn B, White J, Goolsby Hunter A, Essoi B, Elliott C, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2020 Sep 25; 15():2715-2725. PubMed ID: 33149569
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol.
    Moretz C, Bengtson LG, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R.
    Int J Chron Obstruct Pulmon Dis; 2019 Sep 25; 14():2047-2060. PubMed ID: 31564852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.